MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-03-31.

Income Overview

Net Income
-$30,092
Unit: Dollar

Income Statement
2025-03-31
2024-12-31
2024-09-30
Interest expense
11,429 11,131 10,250
Amortization of discount on convertible notes
4,363 4,314 6,044
Total other income (expense)
-15,792 -15,445 -16,294
Professional fees
9,340 16,020 12,680
General and administrative
4,960 8,007 3,030
Total operating expenses
14,300 24,027 15,710
Net loss
-30,092 -39,472 -32,004
Basic EPS
0 0 0
Diluted EPS
0 0 0
Basic Average Shares
70,772,196 70,765,603 70,472,196
Diluted Average Shares
70,772,196 70,765,603 70,472,196
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net loss-$30,092 Total other income(expense)-$15,792 Total operatingexpenses$14,300 Interest expense$11,429 Amortization of discount onconvertible notes$4,363 Professional fees$9,340 General andadministrative$4,960

NEXIEN BIOPHARMA, INC. (NXEN)

NEXIEN BIOPHARMA, INC. (NXEN)